Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason R Pitarresi

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Science (New York, N.Y.)|July 11, 2024
Unmasking immune suppressionJason R Pitarresi, Katherine A Fitzgerald
Nature Biomedical Engineering|August 14, 2021
Single-cell analysis of ductal differentiationJason R Pitarresi, Anil K Rustgi
Cell Stem Cell|June 4, 2021
Pancreatic plasticity: Unlocking exocrine lineage specificationJason R Pitarresi, Anil K Rustgi
Advances in Experimental Medicine and Biology|October 3, 2019
Mechanisms Underlying Metastatic Pancreatic CancerJason R Pitarresi, Anil K Rustgi
Cold Spring Harbor Perspectives in Medicine|August 21, 2023
Cellular Origins and Lineage Plasticity in CancerJason R Pitarresi, Ben Z Stanger
Cancer Research|April 8, 2025
To EMT or not to EMT: Ablation of mesenchymal tumor cell lineages reveals the essential role of EMT in pancreatic cancer initiation and evolutionJessica Peura, Calvin Johnson, Jason R Pitarresi
Nature Reviews. Cancer|April 29, 2017
The ETS family of oncogenic transcription factors in solid tumoursGina M Sizemore, Jason R Pitarresi, Subhasree Balakrishnan, et al.
Trends in Cell Biology|August 18, 2020
EMT, MET, Plasticity, and Tumor MetastasisBasil Bakir, Anna M Chiarella, Jason R Pitarresi, et al.
Oncogene|February 2, 2019
PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cellsBenoît Marchand, Jason R Pitarresi, Maximilian Reichert, et al.
Science Advances|December 5, 2020
Growth of pancreatic cancers with hemizygous chromosomal 17p loss of <i>MYBBP1A</i> can be preferentially targeted by PARP inhibitorsAntony Hsieh, Jason R Pitarresi, Jonathan Lerner, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Science (New York, N.Y.)|July 11, 2024
Unmasking immune suppressionJason R Pitarresi, Katherine A Fitzgerald
Nature Biomedical Engineering|August 14, 2021
Single-cell analysis of ductal differentiationJason R Pitarresi, Anil K Rustgi
Cell Stem Cell|June 4, 2021
Pancreatic plasticity: Unlocking exocrine lineage specificationJason R Pitarresi, Anil K Rustgi
Advances in Experimental Medicine and Biology|October 3, 2019
Mechanisms Underlying Metastatic Pancreatic CancerJason R Pitarresi, Anil K Rustgi
Cold Spring Harbor Perspectives in Medicine|August 21, 2023
Cellular Origins and Lineage Plasticity in CancerJason R Pitarresi, Ben Z Stanger
Cancer Research|April 8, 2025
To EMT or not to EMT: Ablation of mesenchymal tumor cell lineages reveals the essential role of EMT in pancreatic cancer initiation and evolutionJessica Peura, Calvin Johnson, Jason R Pitarresi
Nature Reviews. Cancer|April 29, 2017
The ETS family of oncogenic transcription factors in solid tumoursGina M Sizemore, Jason R Pitarresi, Subhasree Balakrishnan, et al.
Trends in Cell Biology|August 18, 2020
EMT, MET, Plasticity, and Tumor MetastasisBasil Bakir, Anna M Chiarella, Jason R Pitarresi, et al.
Oncogene|February 2, 2019
PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cellsBenoît Marchand, Jason R Pitarresi, Maximilian Reichert, et al.
Science Advances|December 5, 2020
Growth of pancreatic cancers with hemizygous chromosomal 17p loss of <i>MYBBP1A</i> can be preferentially targeted by PARP inhibitorsAntony Hsieh, Jason R Pitarresi, Jonathan Lerner, et al.
Pageof 6